Abstract
If a biotechnology startup is to be successful, it is most important that the company be able to distinguish those projects that have genuine potential for success from those that do not. Timing is also critical in this empirical process. Discovering too late that a project’s actual product offers only lackluster performance or has a quite limited market can be very expensive to the company because of the inevitable loss of time and of valuable research and development funds, which in some cases can prove fatal. There is no question that proper project planning and continuous monitoring of each project’s progress is essential to the success of a biotechnology company.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Pertinent Reading
Articles
Bangham, D.R. 1988. Reference preparations and matrix effects. in:Complementary Immunoassays.(Ed., W.P. Collins) Wiley, New York, pp. 13–25.
Bangham, D.R. and P.M. Cotes. 1988. Standardiza-tion and standards.Br. Med. Bull. 30: 12–17.
Dutton, G. 1993. One-stop data input may help speed bioproduct development.GEN 13(15):1.
Holbrow, E.J. and G.D. Johnson. 1983. Standardization in immunofluorescence. in:Defined Immunofluorescence and Related Cytochemical Methods.(Eds., E.H. Beutner, R.J. Nisengard, and B. Albini)Ann. NYAcad. Sci.vol. 420, New York, pp. 62–64.
Jeffcoate, S.L. 1982. Standardization ofhCG immunoassays and pregnancy kits.Lanceti:803.
Levy, F.K., G.L. Thompson, and J.D. Wiest. 1963. The ABCs of the critical path method.Harvard Bus. Rev. (September-October)pp. 98–108.
Nonbudgetary Methods of Control. 1978. in:Management.by J.A.F. Foster. Prentice-Hall, Englewood Cliffs, NJ, 618–644.
Pappas, M.G. 1988. Dot-Enzyme-linked immunosorbent assays. in:Complementary Immunoassays.(Ed., W.P. Collins) Wiley, New York, pp. 113–134.
Schonberger, R.J. 1972. Custom-tailored PERT/CPM systems.Bus. Horizons15:64–66.
Seaver, S.S. and M.A. Boss. 1992. Beta-testing of biotechnology products is a requirement, not a luxury: Part I.GEN12(11):4.
Seaver, S.S. and M.A. Boss. 1992. Beta-testing of biotechnology products is a requirement, not a luxury: Part II.GEN12(12):4.
Taylor, R.N. 1983. Measurement of variation and significance in serologic tests. in:Defined Immunofluorescence and Related Cytochemical Methods.(Eds., E.H. Beutner, R.J. Nisengard and B. Albini)Ann. NYAcad. Sci.vol. 420, New York, pp. 13–21.
WHO Expert Committee on Biological Standardization. 1987. 36th Report.WHO Tech. Rep. SeriesNo. 745.
Books
Decision Making Through Operations Research.by R.J. Thierauf and R.A. Grosse. Wiley, New York, 1970.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pappas, M.G. (1994). Biotechnology Product Development. In: The Biotech Business Handbook. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-0293-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4612-0293-6_8
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-7139-7
Online ISBN: 978-1-4612-0293-6
eBook Packages: Springer Book Archive